According to the recommendations of the Polish Dermatological Society dated 2018, cyclosporin A (CsA) and biological drugs, among others TNF-α inhibitors (adalimumab), are recommended for the treatment of moderate and severe cases of psoriasis [24, 25]. The gene discussed is TNF; the disease is psoriasis.